Deferred Tax Assets, Valuation Allowance of Seres Therapeutics, Inc. from 31 Dec 2012 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Seres Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2012 to 31 Dec 2025.
  • Seres Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $310,961,000, a 0.39% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Seres Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $310,961,000 +$1,219,000 +0.39% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q4 2024 $309,742,000 -$3,067,000 -0.98% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q4 2023 $312,809,000 +$35,439,000 +13% 31 Dec 2023 10-K 12 Mar 2026 2025 FY
Q4 2022 $277,370,000 +$57,256,000 +26% 31 Dec 2022 10-K 12 Mar 2026 2025 FY
Q4 2021 $220,114,000 +$26,378,000 +14% 31 Dec 2021 10-K 13 Mar 2025 2024 FY
Q4 2020 $193,736,000 +$36,390,000 +23% 31 Dec 2020 10-K 05 Mar 2024 2023 FY
Q4 2019 $157,346,000 +$25,337,000 +19% 31 Dec 2019 10-K 07 Mar 2023 2022 FY
Q4 2018 $132,009,000 +$37,883,000 +40% 31 Dec 2018 10-K 01 Mar 2022 2021 FY
Q4 2017 $94,126,000 +$11,132,000 +13% 31 Dec 2017 10-K 02 Mar 2021 2020 FY
Q4 2016 $82,994,000 +$50,217,000 +153% 31 Dec 2016 10-K 02 Mar 2020 2019 FY
Q4 2015 $32,777,000 +$22,255,000 +212% 31 Dec 2015 10-K 06 Mar 2019 2018 FY
Q4 2014 $10,522,000 +$6,228,000 +145% 31 Dec 2014 10-K 08 Mar 2018 2017 FY
Q4 2013 $4,294,000 +$2,695,000 +169% 31 Dec 2013 10-K 16 Mar 2017 2016 FY
Q4 2012 $1,599,000 31 Dec 2012 10-K 14 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.